8g2o - Revision history

OCA at 13:10, 1 March 2024

2024-03-01T13:10:52Z

←Older revision		Revision as of 13:10, 1 March 2024
Line 8:		Line 8:
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8g2o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8g2o OCA], [https://pdbe.org/8g2o PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8g2o RCSB], [https://www.ebi.ac.uk/pdbsum/8g2o PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8g2o ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8g2o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8g2o OCA], [https://pdbe.org/8g2o PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8g2o RCSB], [https://www.ebi.ac.uk/pdbsum/8g2o PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8g2o ProSAT]</span></td></tr>
	</table>		</table>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	INTRODUCTION: We discovered that the APOE3 Christchurch (APOE3Ch) variant may provide resistance to Alzheimer's disease (AD). This resistance may be due to reduced pathological interactions between ApoE3Ch and heparan sulfate proteoglycans (HSPGs). METHODS: We developed and characterized the binding, structure, and preclinical efficacy of novel antibodies targeting human ApoE-HSPG interactions. RESULTS: We found that one of these antibodies, called 7C11, preferentially bound ApoE4, a major risk factor for sporadic AD, and disrupts heparin-ApoE4 interactions. We also determined the crystal structure of a Fab fragment of 7C11 and used computer modeling to predict how it would bind to ApoE. When we tested 7C11 in mouse models, we found that it reduced recombinant ApoE-induced tau pathology in the retina of MAPT*P301S mice and curbed pTau S396 phosphorylation in brains of systemically treated APOE4 knock-in mice. Targeting ApoE-HSPG interactions using 7C11 antibody may be a promising approach to developing new therapies for AD.
-
-	APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation.,Marino C, Perez-Corredor P, O'Hare M, Heuer A, Chmielewska N, Gordon H, Chandrahas AS, Gonzalez-Buendia L, Delgado-Tirado S, Doan TH, Vanderleest TE, Arevalo-Alquichire S, Obar RA, Ortiz-Cordero C, Villegas A, Sepulveda-Falla D, Kim LA, Lopera F, Mahley R, Huang Y, Quiroz YT, Arboleda-Velasquez JF Alzheimers Dement. 2023 Oct 4. doi: 10.1002/alz.13436. PMID:37791598<ref>PMID:37791598</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 8g2o" style="background-color:#fffaf0;"></div>
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 14:06, 18 October 2023

2023-10-18T14:06:08Z

←Older revision		Revision as of 14:06, 18 October 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8g2o is ~~ON HOLD until Paper~~ Publication	+	==Fab structure - Anti-ApoE-7C11 antibody==
		+	<StructureSection load='8g2o' size='340' side='right'caption='[[8g2o]], [[Resolution\|resolution]] 1.70Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[8g2o]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8G2O OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8G2O FirstGlance]. <br>
		+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.7Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8g2o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8g2o OCA], [https://pdbe.org/8g2o PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8g2o RCSB], [https://www.ebi.ac.uk/pdbsum/8g2o PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8g2o ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	INTRODUCTION: We discovered that the APOE3 Christchurch (APOE3Ch) variant may provide resistance to Alzheimer's disease (AD). This resistance may be due to reduced pathological interactions between ApoE3Ch and heparan sulfate proteoglycans (HSPGs). METHODS: We developed and characterized the binding, structure, and preclinical efficacy of novel antibodies targeting human ApoE-HSPG interactions. RESULTS: We found that one of these antibodies, called 7C11, preferentially bound ApoE4, a major risk factor for sporadic AD, and disrupts heparin-ApoE4 interactions. We also determined the crystal structure of a Fab fragment of 7C11 and used computer modeling to predict how it would bind to ApoE. When we tested 7C11 in mouse models, we found that it reduced recombinant ApoE-induced tau pathology in the retina of MAPT*P301S mice and curbed pTau S396 phosphorylation in brains of systemically treated APOE4 knock-in mice. Targeting ApoE-HSPG interactions using 7C11 antibody may be a promising approach to developing new therapies for AD.

-	~~Authors~~:	+	APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation.,Marino C, Perez-Corredor P, O'Hare M, Heuer A, Chmielewska N, Gordon H, Chandrahas AS, Gonzalez-Buendia L, Delgado-Tirado S, Doan TH, Vanderleest TE, Arevalo-Alquichire S, Obar RA, Ortiz-Cordero C, Villegas A, Sepulveda-Falla D, Kim LA, Lopera F, Mahley R, Huang Y, Quiroz YT, Arboleda-Velasquez JF Alzheimers Dement. 2023 Oct 4. doi: 10.1002/alz.13436. PMID:37791598<ref>PMID:37791598</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased~~ Structures]]	+	</div>
		+	<div class="pdbe-citations 8g2o" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Arboleda-Velasquez JF]]
		+	[[Category: Marino C]]

OCA: Protected "8g2o" [edit=sysop:move=sysop]

2023-02-15T08:47:18Z

Protected "8g2o" [edit=sysop:move=sysop]

←Older revision

Revision as of 08:47, 15 February 2023

OCA: New page: '''Unreleased structure''' The entry 8g2o is ON HOLD until Paper Publication Authors: Description: Category: Unreleased Structures

2023-02-15T08:47:16Z

New page: '''Unreleased structure''' The entry 8g2o is ON HOLD until Paper Publication Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 8g2o is ON HOLD until Paper Publication

Authors:

Description:
[[Category: Unreleased Structures]]